MiniMed Group (NASDAQ:MMED) Hits New 1-Year Low – Should You Sell?

MiniMed Group Inc (NASDAQ:MMED) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $12.80 and last traded at $13.20, with a volume of 1122969 shares traded. The stock had previously closed at $13.23.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Evercore assumed coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set an “outperform” rating and a $20.00 target price on the stock. Morgan Stanley assumed coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set an “overweight” rating and a $19.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $24.00 target price on the stock. Wall Street Zen upgraded shares of MiniMed Group to a “hold” rating in a research report on Saturday, March 14th. Finally, BTIG Research assumed coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $25.00 target price on the stock. Eleven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Price Performance

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.